Article info
Inflammatory bowel disease
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
- Correspondence to:
Dr G Van Assche
Universitaire Ziekenhuizen Leuven, Inwendige Geneeskunde, UZ Gasthuisberg, Herestraat 49-B–3000, Leuven, Belgium; gert.vanassche{at}uz.kuleuven.ac.be
Citation
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
Publication history
- Revised March 7, 2006
- Accepted March 14, 2006
- First published April 7, 2006.
Online issue publication
October 17, 2006
Article Versions
- Previous version (7 April 2006).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2006 by Gut